Equities Research Analysts’ updated eps estimates for Monday, March 20th:

Aimmune Therapeutics (NASDAQ:AIMT) was downgraded by analysts at Zacks Investment Research from a hold rating to a sell rating. According to Zacks, “Aimmune Therapeutics, Inc. is a biopharmaceutical company which is engaged in the development of desensitization treatments for peanut and other food allergies. The Company’s characterized oral desensitization immunotherapy includes AR101, a product for the treatment of peanut allergy in children and adults which is in clinical trial stage. Aimmune Therapeutics, Inc. is headquartered in Brisbane, California. “

American Midstream Partners (NYSE:AMID) was upgraded by analysts at Zacks Investment Research from a sell rating to a hold rating. According to Zacks, “American Midstream Partners, LP owns, operates, develops and acquire a diversified portfolio of natural gas midstream energy assets. The Company is engaged in the business of gathering, treating, processing and transporting natural gas through its ownership and operation of gathering systems, processing facilities and pipelines. Its primary assets, which are located in Alabama, Louisiana, Mississippi, Tennessee and Texas, provide infrastructure that links producers and suppliers of natural gas to diverse natural gas markets, including various pipelines, as well as utility, industrial and other commercial customers. American Midstream Partners, LP is based in Denver, Colorado. “

This article was originally published by and is the sole property of American Banking News. If you happen to be reading this article on another website, it was stolen and illegally republished in violation of U.S. and International copyright law. The original version of this story can be read at https://www.americanbankingnews.com/2017/03/20/equities-research-analysts-updated-eps-estimates-for-march-20th-aimt-amid-auph-avd-bdref-bpth-cbhmy-cbl-ccl-chu.html

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) was upgraded by analysts at Zacks Investment Research from a sell rating to a hold rating. According to Zacks, “Aurinia Pharmaceuticals Inc. is a late stage biopharmaceutical company. It focuses on the development of therapeutic immunomodulating drug candidate. The company’s lead drug includes Voclosporin for the treatment of lupus nephritis. Aurinia Pharmaceuticals Inc. is headquartered in Victoria, Canada. “

American Vanguard Corp. (NYSE:AVD) was upgraded by analysts at Zacks Investment Research from a sell rating to a hold rating. According to Zacks, “AMERICAN VANGUARD CORP. is a holding company, which through its subsidiaries, is engaged in the manufacturer and formulation of chemicals for crops, human and animal health protection. These chemicals which include insecticides, fungicides, molluscicides, growth regulatorsain, and soil fumigants, are marketed in liquid, powder, and granular forms. “

Beadell Resources (NASDAQ:BDREF) was downgraded by analysts at Zacks Investment Research from a hold rating to a sell rating. According to Zacks, “Beadell Resources Limited is a gold producer. It owns and operates the Tucano gold mine primarily in Brazil. Beadell Resources Limited is based in West Perth, Australia. “

Bio-Path Holdings (NASDAQ:BPTH) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. Zacks Investment Research currently has $0.75 target price on the stock. According to Zacks, “BIO-PATH is developing leading-edge, patented, liposomal drug delivery systems, with two clinical cancer drug candidates ready for the clinic and a third siRNA cancer drug undergoing final pre-clinical development. Bio-Path’s drug delivery technology distributes nucleic acid drugs systemically, throughout the human body, via simple intravenous infusion. The delivery technology can be applied both to double stranded and single stranded nucleic acid compounds with the potential to revolutionize the treatment of cancer and other diseases where drugable targets of disease are well characterized. “

COBHAM (NASDAQ:CBHMY) was downgraded by analysts at Zacks Investment Research from a hold rating to a sell rating. According to Zacks, “Cobham Plc is engaged in designing and manufacturing equipment as well as components for defence and security, aerospace, space, marine and electronic industries. It primarily operates through segments which include Communications and Connectivity, Advanced Electronic Solutions, Mission Systems and Aviation Services. The Communications and Connectivity segment provides communication equipment, law enforcement and national security solutions and satellite communication equipment for land, sea and air applications. The Advanced Electronic Solutions segment provides technology and solutions for intelligence operations and systems to communicate on land, sea and air. The Mission Systems segment provides safety and survival systems for environments, weapons carriage and equipment for fast jets, transport aircraft, rotor craft, remote controlled robots and bomb disposal vehicles for military application. The Aviation Services segment provides outsourced aviation services for military and civil customers as well as “

CBL & Associates Properties (NYSE:CBL) was upgraded by analysts at Zacks Investment Research from a sell rating to a hold rating. According to Zacks, “CBL & Associates Properties, Inc. is a fully integrated real estate investment trust which owns, develops, acquires, leases, manages, and operates regional shopping malls, open-air centers, community centers and office properties. The Company conducts substantially all of its business through its operating partnership. It owns two qualified REIT subsidiaries: CBL Holdings I, Inc. and CBL Holdings II, Inc. CBL & Associates Properties is headquartered in Chattanooga, Tennessee. “

Carnival Corp (NYSE:CCL) was upgraded by analysts at William Blair from a market perform rating to an outperform rating.

China Unicom (Hong Kong) Limited (NYSE:CHU) was upgraded by analysts at Zacks Investment Research from a strong sell rating to a buy rating. The firm currently has $15.00 price target on the stock. According to Zacks, “China Unicom Limited is engaged in the provision of cellular, paging, long distance, data and internet services in the People’s Repulic of China. “

Catalyst Pharmaceuticals (NASDAQ:CPRX) had its buy rating reaffirmed by analysts at HC Wainwright. The firm currently has a $6.00 target price on the stock.

Carrefour Sa Spon (NASDAQ:CRRFY) was upgraded by analysts at Zacks Investment Research from a sell rating to a hold rating. According to Zacks, “Carrefour S.A. operates hypermarkets, supermarkets, convenience stores and cash and carry stores in Europe, the Americas and Asia. Carrefour S.A. is headquartered in Boulogne-Billancourt, France. “

Cytori Therapeutics (NASDAQ:CYTX) was downgraded by analysts at Zacks Investment Research from a hold rating to a sell rating. According to Zacks, “Cytori Therapeutics, Inc. is discovering and developing proprietary cell-based therapeutics utilizing adult stem and regenerative cells derived from adipose tissue, also known as fat. The Company’s preclinical investigational therapies target cardiovascular disease, spine and orthopedic conditions, gastrointestinal disorders, and new approaches for aesthetic and reconstructive surgery. To facilitate processing and delivery of adipose stem and regenerative cells, Cytori has developed its proprietary Celution System to isolate and concentrate a patient’s own stem and regenerative cells in about an hour. This system will dramatically improve the speed in which personalized cell-based therapies can be delivered to patients. “

Countrywide (NASDAQ:CYWDF) was downgraded by analysts at Zacks Investment Research from a hold rating to a sell rating. According to Zacks, “Countrywide plc provides property services which includes estate agency and lettings network. The company’s business unit consists of Retail, London, B2B and Financial Services. Countrywide plc is headquartered in Milton Keynes, the United Kingdom. “

Tableau Software (NYSE:DATA) had its buy rating reiterated by analysts at Rosenblatt Securities. Rosenblatt Securities currently has a $70.00 price target on the stock.

Evoke Pharma (NASDAQ:EVOK) was downgraded by analysts at Zacks Investment Research from a hold rating to a sell rating. According to Zacks, “Evoke Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development of drugs to treat gastrointestinal disorders and diseases. The Company’s lead product candidate, EVK-001, is in late stage clinical testing which is intended for the treatment of diabetic gastroparesis. Evoke Pharma, Inc. is based in San Diego, California. “

POWERSHARES GLBAL FUNDS IRELAND PLC POWERSHARES EQQQ NASDAQ-100 UCITS ETF (NASDAQ:IRELAND) was upgraded by analysts at Wells Fargo & Co from a market perform rating to an outperform rating.

JPMorgan Chase & Co. (NYSE:JPM) had its overweight rating reaffirmed by analysts at Barclays PLC. The firm currently has a $100.00 target price on the stock.

Starbucks (NASDAQ:SBUX) had its outperform rating reiterated by analysts at Wells Fargo & Co. Wells Fargo & Co currently has a $65.00 target price on the stock.

Steel Dynamics (NASDAQ:STLD) had its neutral rating reiterated by analysts at Macquarie.

Receive News & Ratings for Aimmune Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.